آنتی­ بادی CD71 (10F11)

Name: CD71 Antibody Clone 10F11

Description and aplications: CD71 recognizes a 90kDa glycoprotein encoded by a gene located in the chromosomal region3q29. It is a recirculating molecule between extra- and intracellular environment, located on the surface of all proliferating cells, which has an important role in the transcellular transport of iron. It is specifically expressed on the surface of the precursor cells of erythroid line, with reduced expression in reticulocytes and complete loss of expression in mature erythroid elements. In normal tissues is a useful marker in identifying erythroid precursors or dispoyétic cells of the normal bone marrow as the other cells of myeloid lineage or mature erythroid cells are negative. Other cells that can normally express the antibody are placental syncytiotrophoblasts, myocytes, basal keratinocytes, hepatocytes, cells of pancreatic Langerhans islet and spermatocytes. In tumoral lesions CD71 is a marker with diagnostic value for cases of erythroid leukemia, while the dysplastic erythroid precursors have a decreased expression. In all these cases, compared with the staining of Anti-Haemoglobin and glycophorin A antibodies, CD71 is more sensitive and specific for not presenting reaction with the mature erythroid elements, facilitating the interpretation. Similar results are obtained in biopsies fixed in Zenker’s fixative or paraffin. Except erythroid leukemias, the antibody is negative in all primary tumors or metastatic bone marrow lessions.
In extramedullary lymphomas, the antibody is positive in isolated cases of diffuse large B-cell lymphoma, peripheral T lymphomas, large cell anaplastic lymphomas and in the Reed-Sternberg cells of Hodgkin lymphoma. In breast carcinomas, CD71 expression was detected in a group of tumours with luminal and basal genotype (more common in medullary carcinoma) resistant to treatment with Tamoxifen. In experimental studies on breast carcinoma, models using antibodies directed against CD71, an inhibition of cell proliferation and survival has been observed, suggesting CD71 as a possible new therapeutic target in cases of CD71 positive carcinoma.

Composition: anti-human CD71 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: Prokaryotic recombinant protein corresponding to a region of the N terminal intracellular domain of Transferrin Receptor (Human).